Interleukin-2 (IL-2) is a pleiotropic cytokine required for both effector lymphocyte proliferation/differentiation and regulatory T cell expansion/survival. Ability to receive IL-2 signals is defined by the affinity to distinct IL-2-receptor-complexes expressed on each subset of cells. While IL-2 targets anti-tumor cytotoxic lymphocytes (CTLs) for the treatment of patients with melanoma or renal cell carcinoma, IL-2 directed at regulatory T (Treg) cells could have potential therapeutic value in several immune-related diseases including chronic graft-versus-host disease (cGVHD), type 1 diabetes (T1D) and systemic lupus erythematosus (SLE). A variety of IL-2 alteration has been made to deliver IL-2 to the proper target, including mutant IL-2, IL-2-fusion proteins and anti-IL-2 antibodies. Experimental and clinical trials using IL-2 are expanding to diverse group of diseases including solid organ transplantation. Although the sustainability and efficiency of IL-2-responding cells in controlling disease activity are still not fully understood, the results of clinical trials will provide a basis of the most effective regimen for each disease.

中文翻译：

---

天然和修饰的IL-2，可用于治疗癌症和自身免疫性疾病。

白细胞介素2（IL-2）是效应淋巴细胞增殖/分化和调节性T细胞扩增/存活所必需的多效性细胞因子。接收IL-2信号的能力由对每个细胞子集上表达的不同IL-2受体复合物的亲和力定义。尽管IL-2靶向抗肿瘤细胞毒性淋巴细胞（CTL）来治疗黑色素瘤或肾细胞癌患者，但针对调节性T（Treg）细胞的IL-2可能在包括慢性移植物在内的多种免疫相关疾病中具有潜在的治疗价值。 -宿主疾病（cGVHD），1型糖尿病（T1D）和系统性红斑狼疮（SLE）。已经进行了各种IL-2改变以将IL-2传递至适当的靶标，包括突变体IL-2，IL-2-融合蛋白和抗IL-2抗体。使用IL-2的实验和临床试验正在扩展到包括实体器官移植在内的多种疾病。尽管仍未完全了解应答IL-2的细胞在控制疾病活动中的可持续性和效率，但临床试验的结果将为每种疾病的最有效治疗方案提供基础。